- Accession Number
Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.
Drug Drug Description Darbepoetin alfa A recombinant form of human erythropoietin used to increase differentiation of progenitor cells to red blood cells in the treatment of anemia. Erythropoietin A recombinant form of human erythropoietin used to increase differentiation of progenitor cells to red blood cells in the treatment of anemia. Pegfilgrastim A recombinant human granulocyte colony stimulating factor used to stimulate the production of neutrophils and prevent febrile neutropenia or infections after myelosuppressive chemotherapy. Sargramostim A modified form of recombinant human granulocyte-macrophage colony stimulating factor used to increase immune cell production after myelosuppressive therapy or bone marrow transplant. Drotrecogin alfa A form of recombinant activated human protein C used to reduce mortality in patients with severe sepsis by inhibiting coagulation Factors V and VIII. Alpha-1-proteinase inhibitor A purified form of human alpha-1 proteinase inhibitor used to treat emphysema patients with associated alpha-1 proteinase inhibitor deficiency. Filgrastim A form of recombinant human granulocyte colony stimulating factor used to induce the production of granulocytes and lower infection risk after myelosuppressive therapy. Thyroglobulin For the treatment of hypothyroidism (deficiency in the production of thyroid hormone). Adecatumumab Investigated for use/treatment in breast cancer and prostate cancer. Romiplostim A fusion protein thrombopoietin (TPO) peptide analog that increases platelet counts by binding to and activating the human TPO receptor. Used to treat thrombocytopenia associated with chronic immune thrombocytopenia (ITP). Maxy-G34 Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics. Thrombomodulin Alfa Investigated for use/treatment in blood preservative, blood (blood forming organ disorders, unspecified), sepsis and septicemia, and thrombosis. PRO-542 Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications. Pegdinetanib Investigated for use/treatment in cancer/tumors (unspecified) and macular degeneration. Human C1-esterase inhibitor A C1 inhibitor used to prevent angioedema attacks associated with hereditary angioedema. Thrombopoietin Investigated for use/treatment in thrombocytopenia. TG4010 Investigated for use/treatment in breast cancer, renal cell carcinoma, prostate cancer, and lung cancer. Methoxy polyethylene glycol-epoetin beta A synthetic erythropoiesis stimulating agent (ESA) used to treat anemia associated with chronic kidney disease. Gastric intrinsic factor Intrinsic factor is not currently available in any FDA or Health Canada approved products. However, it is currently in the marketed (but unapproved) product Hematogen in combination with cyanocobalamin (synthetic... Protein C A medication used to treat protein C deficiency leading to purpura fulminans or coumarin-induced skin necrosis. Epoetin delta Epoetin Delta is an ingredient in the EMA-withdrawn product Dynepo. Muplestim Muplestim is under investigation in clinical trial NCT00002258 (A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in... Molgramostim Molgramostim has been used in trials studying the treatment of Bronchiectasis, Cystic Fibrosis, Pulmonary Alveolar Proteinosis, Acute Respiratory Distress Syndrome, and Autoimmune Pulmonary Alveolar Proteinosis. Tecemotide Tecemotide has been used in trials studying the treatment of Prostate Cancer and Carcinoma, Non-Small-Cell Lung. Balugrastim Balugrastim has been used in trials studying the treatment of Solid Tumors. Lenograstim The drug is used to reduce the risk of life-threatening infection in patients with neutropenia, particularly after cytotoxic chemotherapy. Lenograstim is indicated as a treatment to reduce the duration of... Protein S human A medication used for emergency reversal of coagulation factor deficiency in vitamin K antagonist therapy. Lipegfilgrastim A medication used to reduce the duration of chemotherapy-induced neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy. Sulglicotide Not Annotated Regramostim Investigated for use/treatment in adverse effects (chemotherapy) and bone marrow transplant. PRM-151 PRM-151 is under investigation in clinical trial NCT01981850 (A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis). Recombinant CD40-ligand Recombinant CD40-ligand is under investigation in clinical trial NCT00053391 (Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma). Leridistim Leridistim is under investigation in clinical trial NCT00004215 (Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia). Fibronectin Fibronectin is under investigation in clinical trial NCT01812239 (Vaginal Progesterone in Twins With Short Cervix). Avidin Avidin is under investigation in clinical trial NCT00345618 (Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach). Alefacept A recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis. SOR-C13 SOR-C13 is under investigation in clinical trial NCT01578564 (Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel). Talactoferrin alfa Investigated for use/treatment in adverse effects (chemotherapy), cancer/tumors (unspecified), diabetic foot ulcers, lung cancer, solid tumors, and ulcers. Lactoferrin Lactoferrin is under investigation in clinical trial NCT03748043 (The Effectiveness of Lactoferrin in Treatment of Iron Deficiency Anemia in Children With Chronic Tonsillitis). Tengonermin Tengonermin, also known as NGR-hTNF, is a vascular-targeting drug. It is a recombinant protein and peptide-targeted agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide....
- Drugs & Drug Targets